Revolution Medicines insider files Form 144 to sell 10,000 shares
Rhea-AI Filing Summary
Form 144 notice for Revolution Medicines, Inc. (RVMD) reporting a proposed sale of 10,000 common shares acquired and to be sold on 09/02/2025 following an exercise of stock options. The broker listed is Morgan Stanley Smith Barney LLC and the aggregate market value of the shares at filing is $379,700.00. The filing states the issuer has 186,933,190 shares outstanding. The seller previously disposed of 2,170 common shares on 06/16/2025 for $86,431.10. The filer affirms no undisclosed material adverse information and includes standard Rule 10b5-1/attestation language.
Positive
- Transparent disclosure of the proposed sale, including broker, dates, and aggregate market value
- Compliance with Rule 144 and attestation regarding undisclosed material information
- Transaction clearly documented as an exercise of stock options with cash payment
Negative
- None.
Insights
TL;DR: Routine Rule 144 disclosure of an option exercise and proposed sale; not materially large relative to shares outstanding.
The Form 144 documents a 10,000-share sale tied to an option exercise on the same date, routed through Morgan Stanley Smith Barney LLC, with an aggregate market value of $379,700. Compared with the stated 186,933,190 shares outstanding, the position is immaterial in size and consistent with routine executive liquidity. The recent prior sale of 2,170 shares for $86,431.10 is also disclosed. This filing primarily reflects compliance with Rule 144 and public disclosure requirements rather than a material corporate development.
TL;DR: Proper insider disclosure and attestation present; no immediate governance red flags in the filing.
The notice includes the required attestation that the seller is unaware of undisclosed material adverse information and documents transaction mechanics (option exercise, cash payment). The broker and dates are specified, and recent sales within three months are disclosed, showing adherence to disclosure protocols. There is no indication in this form of unusual trading patterns or governance concerns based solely on the provided data.